# A Randomized Trial of the Rapamycin Target Eluting Stent for the Treatment of Symptomatic Cerebral Artery Atherosclerotic Disease（TARGET-DREAM）

> **NCT06925971** · PHASE3 · NOT_YET_RECRUITING · sponsor: **MicroPort NeuroTech Co., Ltd.** · enrollment: 279 (estimated)

## Conditions studied

- Intracranial Arteriosclerosis

## Interventions

- **DEVICE:** Experimental Device A, a self-expanding rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China)
- **DEVICE:** Experimental Device B, a balloon-expandable rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China)
- **DEVICE:** Apollo® Intracranial Artery Stent System, a balloon-expandable bare-metal stent (MicroPort NeuroTech, Shanghai, China),

## Key facts

- **NCT ID:** NCT06925971
- **Lead sponsor:** MicroPort NeuroTech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2027-10-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 279 (ESTIMATED)
- **Last updated:** 2025-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06925971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06925971, "A Randomized Trial of the Rapamycin Target Eluting Stent for the Treatment of Symptomatic Cerebral Artery Atherosclerotic Disease（TARGET-DREAM）". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06925971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*